Alle Studien
Aktiv, aber nicht rekrutierendPHASE3INTERVENTIONELL

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

This research is looking at two different medicines, luspatercept and epoetin alfa, to treat a blood condition called myelodysplastic syndromes (MDS). People with MDS often have low red blood cell counts (anemia) and need regular blood transfusions. The main goal of this study is to find out if luspatercept is better than epoetin alfa at helping people become transfusion-independent, meaning they no longer need regular blood transfusions, and if it can also increase their red blood cell levels. The study focuses on people with specific types of MDS risk who haven't tried similar treatments before.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE3
Sponsor
Celgene
Einschreibeziel
363
Starten
02 Jan 2019
Geschätzte Fertigstellung
28 Sep 2027

Ergebnisse

Ergebnisse dieser Studie

Veröffentlicht June 2024

Die Ergebnisse dieser Studie wurden veröffentlicht.

Hauptausgang
Percentage of Participants With Red Blood Cell Transfusion Independence (RBC-TI) for 12 Weeks (84 Days) With a Mean Hemoglobin Increase ≥ 1.5 g/dL
Percentage of participants who are RBC transfusion-free for any 12-week period associated with a concurrent mean hemoglobin (Hgb) increase ≥ 1.5 g/dL compared to baseline. After applying below 14/3-day rule, the baseline Hgb value is defined as the lowest Hgb value from the central, local laboratory, or pre transfusion Hgb from transfusion records that is within 56 days on or prior to the first dose of treatment, or randomization date if participants were not treated. 4/3-day rule: only Hgb values that are at least 14 days after a transfusion may be used unless there is another transfusion within 3 days after the Hgb assessment. If this occurs, that Hgb value will be used despite being \< 14 days after the previous transfusion.
Vollständige Ergebnisse im Register

Worum geht es in dieser Studie?

You're reading about a research study for people with a blood condition called myelodysplastic syndromes, or MDS. MDS affects your bone marrow, which is the soft, spongy tissue inside your bones where new blood cells are made. In MDS, the bone marrow doesn't produce enough healthy blood cells, especially red blood cells. When you don't have enough healthy red blood cells, you can develop a condition called anemia, which can make you feel very tired and weak, and you might need regular blood transfusions.

This study is comparing two different medicines: luspatercept (sometimes called ACE-536) and epoetin alfa. Epoetin alfa is a common treatment that helps your body make more red blood cells. Luspatercept is a newer medicine, and researchers want to see if it works better than epoetin alfa. The main aim is to see if these medicines can help people with MDS stop needing blood transfusions for at least 12 weeks, and also increase their red blood cell count.

This is a 'Phase 3' study, which means it's one of the final steps in testing a new medicine to make sure it's both safe and effective before it can be widely used. Taking part in a study like this helps doctors learn more about the best ways to treat MDS, which can benefit many people in the future.

Wichtige Erkenntnisse

  • This study compares luspatercept and epoetin alfa for MDS.
  • The main goal is to reduce the need for blood transfusions.
  • It's a Phase 3 study, meaning it's a final step in testing a new medicine.
  • You will receive regular check-ups and blood tests if you participate.
  • Participation could help improve future treatments for MDS.
  • You can stop participating at any time without affecting your care.

Wer könnte berechtigt sein?

To join this study, doctors will first check if you have myelodysplastic syndromes (MDS) and if your condition is considered 'very low', 'low', or 'intermediate' risk. This is based on specific criteria that doctors use to classify MDS. An important part of joining is that you must be needing regular red blood cell transfusions. Specifically, you would have received between two and six units of blood every eight weeks for at least two months before the study starts. You also shouldn't have tried treatments like epoetin alfa before.

There are also some reasons why you might not be able to join. For example, if your anemia is caused by other easily treatable things like a lack of iron or vitamins, or if you have certain other serious health problems. You also wouldn't be able to join if you have a known history of acute myeloid leukaemia (AML) or if your blood pressure is not well controlled even with medication. The medical team will check all these carefully with you.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I have been diagnosed with MDS.
  2. My MDS is classified as 'very low', 'low', or 'intermediate' risk.
  3. I currently need regular red blood cell transfusions (2-6 units every 8 weeks).
  4. I have not previously taken similar medications like epoetin alfa.
  5. I am generally well enough to participate in a study.
  6. My blood pressure is generally well-controlled.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, you'll be assigned to receive either luspatercept or epoetin alfa. Neither you nor your doctor will get to choose which medicine you receive, and often you won't know which one it is (this is called a 'blinded' study). You'll have regular visits to the clinic for medical check-ups, blood tests, and to receive your study medicine. These visits will help the doctors monitor how you're doing, check your blood counts, and look for any side effects. The total duration of your participation in the study will depend on how you respond to the treatment and the study's design, but it will involve ongoing assessments and follow-up care.

Potenzielle Risiken und Vorteile

Taking part in any medical study has potential benefits and risks. A potential benefit could be that the study medicine helps improve your anemia and reduces your need for blood transfusions. However, it's also possible that the study medicine may not work for you, or you might experience side effects. All medical treatments carry some level of risk. Your doctors will explain all known side effects for both medicines. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (226)

  • Local Institution - 107
    Verifizierte Postleitzahl
    Berkeley, Vereinigte Staaten
  • Local Institution - 115
    Verifizierte Postleitzahl
    San Diego, Vereinigte Staaten
  • Local Institution - 101
    Verifizierte Postleitzahl
    Whittier, Vereinigte Staaten
  • Local Institution - 104
    Verifizierte Postleitzahl
    New Haven, Vereinigte Staaten
  • Local Institution - 136
    Verifizierte Postleitzahl
    Washington D.C., Vereinigte Staaten
  • Local Institution - 119
    Verifizierte Postleitzahl
    Hudson, United States
  • Local Institution - 120
    Verifizierte Postleitzahl
    St. Petersburg, Vereinigte Staaten
  • Local Institution - 122
    Verifizierte Postleitzahl
    Tallahassee, Vereinigte Staaten
  • Local Institution - 108
    Verifizierte Postleitzahl
    Tampa, Vereinigte Staaten
  • Local Institution - 118
    Verifizierte Postleitzahl
    West Palm Beach, Vereinigte Staaten
  • Local Institution - 102
    Verifizierte Postleitzahl
    Paducah, United States
  • Local Institution - 123
    Verifizierte Postleitzahl
    Bethesda, Vereinigte Staaten

Häufige Fragen

What is MDS?

MDS (Myelodysplastic Syndromes) is a condition where your bone marrow doesn't make enough healthy blood cells, often leading to low red blood cell counts and anemia.

What does 'transfusion independence' mean?

It means you no longer need regular blood transfusions because your body is making enough red blood cells on its own, or with the help of medication.

Why can't I choose which medicine I get?

In studies like this, treatments are often given randomly, and sometimes neither you nor your doctor knows which medicine you are receiving. This helps ensure the study results are fair and unbiased.

What if I experience side effects?

The study team will closely monitor you for any side effects and will provide care and advice. You should always tell them about any new or worsening symptoms.

Kann ich die Studie jederzeit verlassen?

Yes, you have the right to withdraw from the study at any point, and this will not affect your future medical care.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.